Form 4: TELA Bio Director William Plovanic Receives Equity Grant

Director William J. Plovanic acquired 11,675 restricted stock units and 17,335 stock options as part of an annual equity grant.

Summary

• Director William J. Plovanic was granted 11,675 restricted stock units (RSUs) on June 9, 2026.
• The director also received a stock option grant for 17,335 shares with an exercise price of $0.935 per share.
• Both the RSUs and the stock options are scheduled to vest on the earlier of June 9, 2027, the next annual meeting of stockholders, or a change in control.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standardized vesting schedule tied to continued service.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of options and vesting of RSUs.

Risks

• Vesting is subject to the director's continued service, creating a dependency on personnel retention.
• The value of the equity is subject to market volatility of TELA common stock.

Future Outlook

The equity grants are subject to standard vesting conditions, aligning the director's long-term incentives with the company's performance through June 2027.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the medical device and biotechnology sectors to ensure board alignment with long-term shareholder value.

Comparison to Industry Standards

• The grant structure follows standard industry practices for board compensation in small-cap healthcare companies.
• Vesting periods of one year or until the next annual meeting are consistent with typical director compensation policies.

Stakeholder Impact

• Minor dilution impact for existing shareholders upon future exercise of options.

Next Steps

• Vesting of equity grants on June 9, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

TELA Bio, Form 4, Insider Transaction, Equity Compensation, Director Grant